Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarvajit Chakravarty

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Aaron N Nguyen, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogueBabu J Mavunkel, Sarvajit Chakravarty, John J Perumattam, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 17, 2006
A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone lossKeith L Kirkwood, Fei Li, Jill E Rogers, et al.
Journal of Molecular and Cellular Cardiology|December 2, 2004
p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cellsMoon Y Lim, Hui Wang, Ann M Kapoun, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2009
Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitorsBabu J Mavunkel, John J Perumattam, Xuefei Tan, et al.
ACS Pharmacology & Translational Science|July 20, 2023
Induction of Aryl Hydrocarbon Receptor-Mediated Cancer Cell-Selective Apoptosis in Triple-Negative Breast Cancer Cells by a High-Affinity BenzimidazoisoquinolineDaniel J Elson, Bach D Nguyen, Sebastian Bernales, et al.
Biochemical Pharmacology|July 28, 2023
Suppression of Ah Receptor (AhR) increases the aggressiveness of TNBC cells and 11-Cl-BBQ-activated AhR inhibits their growthDaniel J Elson, Bach D Nguyen, Nicholas A Korjeff, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 7, 2006
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritisSatyanarayana Medicherla, Jing Ying Ma, Ruban Mangadu, et al.
Pharmacology, Biochemistry, and Behavior|July 1, 2008
Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced painCamilla I Svensson, Satyanarayana Medicherla, Shelle Malkmus, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2016
Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SARAmantullah Ansari, Sharad Satalkar, Varshavekumar Patil, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Aaron N Nguyen, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogueBabu J Mavunkel, Sarvajit Chakravarty, John J Perumattam, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 17, 2006
A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone lossKeith L Kirkwood, Fei Li, Jill E Rogers, et al.
Journal of Molecular and Cellular Cardiology|December 2, 2004
p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cellsMoon Y Lim, Hui Wang, Ann M Kapoun, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2009
Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitorsBabu J Mavunkel, John J Perumattam, Xuefei Tan, et al.
ACS Pharmacology & Translational Science|July 20, 2023
Induction of Aryl Hydrocarbon Receptor-Mediated Cancer Cell-Selective Apoptosis in Triple-Negative Breast Cancer Cells by a High-Affinity BenzimidazoisoquinolineDaniel J Elson, Bach D Nguyen, Sebastian Bernales, et al.
Biochemical Pharmacology|July 28, 2023
Suppression of Ah Receptor (AhR) increases the aggressiveness of TNBC cells and 11-Cl-BBQ-activated AhR inhibits their growthDaniel J Elson, Bach D Nguyen, Nicholas A Korjeff, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 7, 2006
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritisSatyanarayana Medicherla, Jing Ying Ma, Ruban Mangadu, et al.
Pharmacology, Biochemistry, and Behavior|July 1, 2008
Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced painCamilla I Svensson, Satyanarayana Medicherla, Shelle Malkmus, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2016
Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SARAmantullah Ansari, Sharad Satalkar, Varshavekumar Patil, et al.
Pageof 4